

**CCG Register of  
Hospitality, Gifts and Sponsorship**

Last Updated: 15/03/2021

CCG Contact: Gemma Richardson, Corporate Governance Manager

Telephone: 01494 586760 Email: [Gemma.richardson14@nhs.net](mailto:Gemma.richardson14@nhs.net)

NOTE: The published register dates from 1 January 2014. NHS Buckinghamshire CCG came into effect 1 April 2018, therefore prior to this, entries on the register relate to gifts, hospitality and sponsorship related to predecessor organisations NHS Aylesbury Vale CCG and NHS Chiltern CCG.

Ref Number	Recipient Name	Position within CCG	Date of offer	Declined or Accepted?	Date of Receipt (if applicable)	Details of Hospitality/Gift/Sponsorship	Estimated Value (plus VAT)	Supplier / Offeror Name and Nature of business	Details of the officer endorsing and authorising the declaration made and date	Reason for Accepting or Declining	Other comments
69	Robert Majilton	Deputy Chief Officer	26/04/2019	Accepted	20/06/2019 to 24/06/2019	Trip to Montenegro as guest – spouse has won as part of employee award scheme. This is a paid for holiday (provided by spouses employer Vodafone)	Unknown	Vodafone	Lou Patten, Chief Officer BCCG	Not stated	None
70	Gill Dunn	Diabetes Specialist Nurse	01/08/2019	Accepted	05/10/2019	Teaching/ facilitation payment	£699	Sanofi Aventis Sahiba Matta-Sandher Diabetes Account Executive Mob. +44 (0) 7595 191471 Sahiba.matta@sanofi.com	Lori Williamson Transformation Manager Long Term Conditions, Ill Health Prevention & Supported Self Care	Content and delivery of sessions have been seen and confirmed as non-promotional and therefore not a conflict of interest.	Discussed with manager- as the content and delivery of session was non-promotional there was not a conflict of interest. Delivering on a non working day for CCG/in own time.
71	Gill Dunn	Diabetes Specialist Nurse	05/08/2019	Accepted	05/08/2019	Interface Clinical Service specialist pharmacist time spent in primary care member practices on diabetes management	£37,500	GlucoRx, offers a market leading range of diabetic products and glucose testing solutions for type 1 & type 2 diabetes.	Gary Henage, Chief Finance Officer, 06/08/19 CCG policy requires authorisation of sponsorship agreements above £25k (cumulative) by CCG Executive Committee. However voting members who are also partners in their member practices are directly and materially conflicted given participation in project and switches to alternative products would affect their prescribing budgets.	Higher than average cost currently spent on blood glucose equipment - related project to review current prescriptions and opportunity to switch to lower cost alternatives. The CCG do not have the capacity to be able to deliver this work through the medicines management team and GPs do not have the capacity to do this work themselves therefore Bucks CCG has proposed a project working with GlucoRx and Interface Clinical Services (ICS) to review patient use of blood glucose meters.	Interface Clinical Services estimate day rate and average number of days working in each practice to estimate highest estimate sponsorship value. Initial estimate – £250 per day x average 3 days per practice x 50 practices = £37,500. This may not play out in reality as some practices may require less involvement, and it is at the direction of practices as to whether they take part in the project. These are felt to be as accurate estimates as they can be, either way.
72	Elaine Baldwin	ICP Programme Manager	03/01/2020	Accepted	08/01/2020	Fully complimentary delegate pass for Healthcare Strategy Forum on 21st & 22nd April. Includes: Access to seminars On site accommodation All meals & refreshments Seat at networking dinner on 21st April	£995	AH Media UK Nature: Events Analytics & Research	Robert Majilton, Deputy Chief Officer. Over a value of £75* should be refused unless (in exceptional circumstances) senior approval is given. A clear reason should be entered on an organisation's register of hospitality, gifts and sponsorship as to why it was permissible to accept.	This forum will be valuable to attend particularly as a development opportunity and to give information on other options which may support financial and operational sustainability along with that more strategic view which is to be developed.	Approval evidence in folder. Declaration forms altered to correct year (2020)
73	Noel Burkett	Head of Portfolio Office	03/01/2020	Accepted	08/01/2020	Fully complimentary delegate pass for Healthcare Strategy Forum on 21st & 22nd April. Includes: Access to seminars On site accommodation All meals & refreshments Seat at networking dinner on 21st April	£995	AH Media UK Nature: Events Analytics & Research	Robert Majilton, Deputy Chief Officer. Over a value of £75* should be refused unless (in exceptional circumstances) senior approval is given. A clear reason should be entered on an organisation's register of hospitality, gifts and sponsorship as to why it was permissible to accept.	This forum will be valuable to attend particularly as a development opportunity and to give information on other options which may support financial and operational sustainability along with that more strategic view which is to be developed.	Approval evidence in folder. Declaration forms altered to correct year (2020)
74	Bucks CCG Executive Committee	Associate Director of Medicines Management and Chief Finance Officer	27/02/2020	Accepted	-	Joint Management – funding through grant agreement and Lipid Working Agreements (JWA) with the pharmaceutical industry. Project Title: Transforming Lipid Management in Primary care in Buckinghamshire	£50k through 2020/21.	Pharmaceutical joint working frameworks/agreements (incorporating project initiation documents) for lipid management (PCSK9 inhibitors) joint working agreements with pharmaceutical suppliers, namely Amgen and Sanofi	Delegated authority to the Associate Director of Medicines Management and Chief Finance Officer to approve financial implications as patient numbers and more accurate predictions of budget impact emerge. Executive Committee: 27/02/2020	The CCG entering into joint working agreements with pharmaceutical suppliers, namely Amgen and Sanofi, with funding aligned to joint working agreements received by the CCG for subsequent investment/deployment. It is intended for use, amongst other things, to create a sustainable Pharmacist Led service that will be developed and delivered by a Clinical Pharmacist Independent Prescriber. The Pharmacist will likely be employed by Buckinghamshire Healthcare NHS Trust (B&K).	These agreements will also be reported to the CCG Governing Body through the accountable officer report in March 2020.
75	Dr Raji Thakkar	Clinical Director Planned Care, Buckinghamshire CCG	05/06/2020	Declined	N/A	Invitation to join AstraZeneca National Heart Failure Steering Committee: role would be to attend the National Steering Committee meeting to share best practice and input your expertise in the development of the patient pathway. The non-promotional meeting (and contract) will consist of a 9:00-16:00 virtual meeting with 1 hour pre-work, 3 hours of post-work and 2 hours of project implementation (total 13 hours at £200/hr = £2,600).	£2,600	AstraZeneca- UKMC, Medical and Scientific Affairs. Katrina Mullin, Ph.D. Medical Affairs Lead, Cardiovascular	Not Applicable- declined	BCCG policy statement (Gifts, Hospitality and sponsorship): Advisory panels/boards: Requests to participate on advisory boards, fee paid or not, should be considered on a case by case basis, and include only those managed by public authorities such as universities or educational academies. Any other requests, including pharmaceutical companies, should be politely declined and declared – irrespective of whether advisory board relates to a drug which is or is not on the formulary.	None
76	Robert Majilton	Deputy Chief officer/ Deputy Accountable Officer	19/10/2020	Accepted	Nov-20	BA/Avios Points Offer  In May 2020 Avios Group and British Airways launched an appeal to members to donate their Avios points to NHS workers as a thank you in recognition of work carried out in response to the COVID-19 pandemic. 300 million Avios were donated. The B&K CCGs have the opportunity to nominate someone to receive Avios points, one from each CCG.	£600 (600,000 avios points = £600)	Avios Group, the loyalty business in the International Airlines Group and supply's the loyalty currency.	CCG Director of Governance and Deputy Chief Executives.	Policy: Any gift or offer of a gift from sources such as patients, families and service users which is perceived to or does exceed £50 must be declared, declared and entered in the register. This offer is above the threshold. However: • We are in exceptional times and this has come from individual members of Avios donating small numbers of points each • This is a national offer • This is not directed to a specific individual/organisation by a potential supplier/individual – and our GBH policies are more about this direct offer • This is something we should make available as our staff have like other NHS staff have contributed in very difficult circumstances.  Additional Conditions: Nominees will need to become a member of the Avios Points scheme to receive and use the points. They will be asked if they want to share their stories, but this is entirely optional.	-
77	James Limehouse	Senior CHC Commissioner	24/12/2020	Accepted	24/12/2020	Gift Hamper consisting mainly of homemade baked goods	£25	OHFT CHC Service Manager	Russell Carpenter, Head of Governance	The gift was offered with no conditions with the intention that it be non work related	None
78	Jane Buterworth	Associate Director- Medicines Management	Mar-21	03-Mar-21	Mar-21	Joint Working agreement- Bayer Pharmaceuticals Anticoagulation education.  A joint working agreement is known to have been entered into during Quarter 4 2020/2021, reported for information to the CCG Governing Body on 11 March 2021. This is with Bayer Pharmaceuticals for a dual branded webinar based education programme on anticoagulants delivered by Bayer employed clinicians. This includes 4 market products already available on formulary so there is no specific favouritism towards Bayer products.  The agreement is deemed to fall within a policy definition that the CCG will support "funding to facilitate training and educational initiatives that are aimed at improving the management of a condition".  Although there is a nil transfer value to the CCG, the likely cost of sponsor staffing for the education events described within the agreement (i.e. above £500) will have director level authorisation. It will also be declared on the CCG register and be reported to audit committee in line with CCG policy.	£25	Bayer Pharmaceutical company	Head of Governance and Associate Director of Medicines Management have worked through and completed the template with necessary comments incorporated accordingly. A sponsor signature is deemed not required given there is a nil transfer of value to the CCG and therefore explicit financial commitment. Current CCG policy does not explicitly state a sponsor signature is required. It does state that each agreement is declared and reported to audit committee for which this agreement is no different. This agreement is deemed to fall within a policy definition that the CCG will support "funding to facilitate training and educational initiatives that are aimed at improving the management of a condition".  Although there is a nil transfer value, the likely cost of sponsor staffing for the education events described within this agreement (i.e. above £500) is therefore deemed to require director level authorisation.		